Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2020-09-01 10:19:50New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
-
Daiichi Sankyo2023-11-09 20:59:16NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
-
Daiichi Sankyo2023-11-09 20:59:05ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
-
Daiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Daiichi Sankyo2020-08-03 09:24:40Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice
-
Daiichi Sankyo2020-08-03 09:25:37Bempedoic Acid Lowers LDL-Cholesterol without Adversely Impacting Glycaemic Control in Pooled Analyses of
-
Daiichi Sankyo2020-08-03 09:26:30Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom
-
Daiichi Sankyo2020-08-03 09:28:15Pooled Analyses of Bempedoic Acid Phase 3 LDL-C Lowering Clinical Trial Programme to be Presented at the
-
Daiichi Sankyo2020-08-03 09:30:42European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly
-
Daiichi Sankyo2020-08-03 09:31:20ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in